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Abstract 
Background: BRAF V600 mutant circulating cell-free tumor DNA (BRAF V600mut ctDNA) could serve as a specific 
biomarker in patients with BRAF V600 mutant melanoma. We analyzed the value of BRAF V600mut ctDNA from  
plasma as a monitoring tool for advanced melanoma patients treated with BRAF/MEK inhibitors.
Methods: Allele-specific quantitative PCR analysis for BRAF V600 E/E2/D/K/R/M mutations was performed on DNA 
extracted from plasma of patients with known BRAF V600 mutant melanoma who were treated with dabrafenib and 
trametinib.
Results: 245 plasma samples from 36 patients were analyzed. In 16 patients the first plasma sample was obtained 
before the first dosing of dabrafenib/trametinib. At baseline, BRAF V600mut ctDNA was detected in 75 % of patients 
(n = 12/16). BRAF V600mut ctDNA decreased rapidly upon initiation of targeted therapy (p < 0.001) and became 
undetectable in 60 % of patients (n = 7/12) after 6 weeks of treatment. During treatment, disease progression (PD) 
was diagnosed in 27 of 36 patients. An increase of the BRAF V600mut ctDNA copy number and fraction, identified PD 
with a sensitivity of 70 % (n = 19/27) and a specificity of 100 %. An increase in the BRAF V600mut ctDNA fraction was 
detected prior to clinical PD in 44 % of cases (n = 12/27) and simultaneously with PD in 26 % of patients (n = 7/27).
Conclusions: Quantitative analysis of BRAF V600mut ctDNA in plasma has unique features as a monitoring tool 
during treatment with BRAF/MEK inhibitors. Its potential as an early predictor of acquired resistance deserves further 
evaluation.
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Background
The detection of mutations in circulating cell-free tumor 
DNA (ctDNA) is under investigation as a specific bio-
marker for the diagnosis and monitoring of patients with 
different cancer types [1–4]. Mutations in the BRAF gene 
at position V600 are detected in 40–50  % of cutaneous 
melanomas, and represent the most common oncogenic 
driver mutation in this disease [5]. Therefore, quantita-
tive measurement of BRAF V600 mutant ctDNA in cell-
free DNA (cfDNA) extracted from plasma could serve as 
a specific biomarker in this patient population [6, 7].
Treatment with a combination of a BRAF- and MEK 
inhibitor results in a high tumor response rate (64–69 %) 
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mutant melanoma [8–10]. Immune-checkpoint inhibition 
of either the CTLA-4 or PD-1 receptor can also improve 
the survival of patients with advanced melanoma, irrespec-
tive of the BRAF V600 mutation status [11–13]. Optimal 
sequencing of available treatment options for patients with 
BRAF V600 mutant melanoma has not been defined. Ret-
rospective series have raised concern that ipilimumab may 
have lesser activity when applied after the emergence of 
resistance to BRAF-inhibitors [14, 15]. Alternatively, ipili-
mumab fails to improve the survival of patients with a life-
expectancy of less than 3–4 months from initiating therapy, 
and durable complete responses have been reported on 
ipilimumab in patients who developed prior resistance to 
treatment with a BRAF-inhibitor [16]. Of concern is the 
high incidence of progression within the central nervous 
system (CNS) at first progression on BRAF-inhibitors, as 
metastases to the CNS often imply a poor prognosis and 
necessitate the use of corticotherapy, implying an unfa-
vorable condition for initiating immunotherapy [17, 18]. 
As conventional clinical tools for assessment of early tumor 
progression lack sensitivity, many patients will be sympto-
matic at the time of progression or will experience rapid 
progression and deterioration in the few weeks that fol-
low the diagnosis of progression [17, 19–21]. Therefore, 
more sensitive tools for monitoring of response and resist-
ance to BRAF/MEK targeted therapy is of interest in order 
to optimize treatment of advanced BRAF V600 mutant 
melanoma. Furthermore, changes in the BRAF V600mut 
ctDNA concentration might be helpful for the interpreta-
tion of imaging results during immunotherapy where atypi-
cal tumor responses are more frequent [22, 23].
In this translational research study we analyze the 
value of longitudinal quantitative measurement of BRAF 
V600mut ctDNA from plasma as a therapeutic monitor-
ing tool for patients with advanced BRAF V600 mutant 
melanoma treated with the BRAF/MEK inhibitors dab-
rafenib and trametinib.
Methods
This was an exploratory translational study with a pri-
mary objective of investigating longitudinal quantita-
tive measurement of BRAF V600mut ctDNA in patients 
treated with a combination of a BRAF and a MEK inhibi-
tor using the Idylla™ ctBRAF Mutation prototype assay 
on the Idylla™ system (Biocartis). The study was con-
ducted at a single university hospital (UZ Brussel, aca-
demic study sponsor) in collaboration with Biocartis 
(Mechelen, Belgium).
Patients were eligible for plasma BRAF V600mut 
ctDNA monitoring when a BRAF V600 mutation had 
been detected in tumor tissue and were either treated 
or initiated treatment with dabrafenib and trametinib. 
Blood samples were prospectively collected after 
obtaining informed consent with an Ethical Committee 
approved document. Response evaluation to targeted 
therapy was performed every 2  months with standard 
imaging techniques [including 18-fluorodeoxyglucose 
positron emission tomography/computed tomography 
(FDG PET–CT), computed tomography (CT) of thorax 
and abdomen, magnetic resonance imaging (MRI) of 
the brain]. Plasma samples were collected together with 
routine blood collections (every 2 weeks during the first 
month of therapy; every month after the first month of 
therapy), until progressive disease (PD) was detected 
according to RECIST v1.1 [24].
Blood samples were collected in 10  mL EDTA tubes 
and immediately centrifuged at a relative centrifugal 
force of 1410.63×g, during 15 min at room temperature. 
Plasma was separated and stored in 1-mL aliquots at 
−80 °C. Silica-based extraction of DNA and subsequent 
allele-specific quantitative PCR (qPCR) to detect the 
BRAF wild-type gene and the G1798>A and T1799>A 
changes in the BRAF gene were performed with Idylla™ 
(Biocartis) on 1 mL of the stored plasma. The G1798>A 
change is present in patients with V600  K, V600R, and 
V600  M mutations, whereas the T1799>A change is 
present in patients with V600E, V600  K, V600E2, and 
V600D mutations. A linear correlation between Cq val-
ues reported by prototype Idylla assays and digital drop-
let PCR was previously established, allowing precise and 
sensitive quantification of mutant ctDNA fragments in 
plasma down to 3 mutant copies per PCR reaction with 
an analytical sensitivity of 0.01 %. The investigators that 
performed the DNA extraction and the subsequent 
qPCR were blinded for the clinical patient information. 
Quantitative PCR results were expressed as median and 
25th/75th percentiles of the BRAF V600mut ctDNA copy 
number per milliliter, and the BRAF V600mut ctDNA 
fraction to the total amount of cfDNA. The evolution of 
the BRAF V600mut ctDNA copy number and fraction, 
were analyzed in relation to the clinical diagnosis of PD. 
Progression-free survival (PFS) was measured from the 
time of first administration of targeted therapy, to the 
time of PD or death, and was analyzed using the Kaplan–
Meier method (SPSS software, IBM). For comparison of 
PFS between different groups, the log-rank test was used. 
We applied the Wilcoxon signed-rank test to compare 
changes in the concentrations during treatment. Fisher’s 
exact test was used to compare categorical variables. A 
2-tailed p value ≤0.05 was considered to be statistically 
significant. Statistical analysis was performed with SPSS 
statistics 22.
To assess the early evolution of the BRAF V600mut 
ctDNA concentration during treatment with dab-
rafenib and trametinib, five samples were collected 
during the first 24  h of treatment in two additional 
Page 3 of 11Schreuer et al. J Transl Med  (2016) 14:95 
patients treated “in hospital”. In these two patients, all 
plasma samples were analyzed in duplicate. The first 
sample of 1  mL was analyzed with the Idylla™ system 
using a fully automated cartridge that contains all rea-
gents for the above mentioned extraction of DNA fol-
lowed by qPCR detection and reporting of the results. 
In the second sample of 1  mL, DNA was extracted 
using the QIAamp Circulating Nucleic Acid Kit (Qia-
gen), followed by droplet digital PCR (ddPCR, Bio-rad) 
for detection of BRAF V600Emut ctDNA. Each ddPCR 
analysis was performed in triplicate. Five μL of eluate 
was added to each ddPCR reaction containing 11.5 μL 
ddPCR Supermix for probes (Bio-Rad) and 3  μL of 
BRAF V600E and wild-type assay (dHsaCP2000027, 
dHsaCP2000028, Bio-Rad), adjusted to a total volume 
of 23  μL. The reaction was then compartmentalized 
into  ~15,000 droplets per sample in a QX-100 droplet 
generator (Bio-Rad) according to the manufacturer’s 
instructions. Emulsified PCR reactions were run in 
96-well format on a Bio-rad CFX96 Touch Real-Time 
PCR Detection System according to the manufacturer’s 
instructions. Plates were subsequently read on a Bio-
Rad QX-100 droplet reader using QuantaSoft software 
(Bio-Rad). No-template controls were included in each 
run and the BRAF V600E copies per sample were quan-
tified using the Quantasoft software.
Results
Patients and procurement of plasma samples
From February 2014 to October 2015, 245 plasma sam-
ples from 36 patients with advanced melanoma were 
collected. Clinical baseline patient characteristics are 
summarized in Table  1. In 16 patients the first plasma 
sample was obtained before the first dosing of dabrafenib 
(150 mg BID) and trametinib (2 mg QD). In 20 patients 
the first sample was obtained after initiation of targeted 
therapy.
Early changes in BRAF V600 mutant ctDNA after treatment 
initiation with dabrafenib/trametinib
In 75 % of patients (n = 12/16) BRAF V600mut ctDNA 
was detected before initiation of dabrafenib and 
trametinib (median fraction 16.5 %; Q1–Q3 9.8–25 %—
median copy number 571 copies/mL; Q1–Q3 79–1610 
copies/mL) (Fig.  1a). In 25  % of patients (n =  4/16) no 
BRAF V600mut ctDNA was detected before initiation of 
dabrafenib and trametinib.
To assess changes in the BRAF V600mut ctDNA con-
centration during the first hours after treatment ini-
tiation, five samples were collected in the first 24  h of 
treatment in 2 patients treated ‘‘in hospital’’ (Fig.  2). In 
both patients the BRAF V600mut ctDNA copy number 
decreased significantly within 5  days after treatment 
initiation. In one patient only a transient increase in 
the BRAF V600mut ctDNA copy number was observed 
within the first 24 h on therapy (Fig. 2b, d).
During treatment, the BRAF V600mut ctDNA frac-
tion and copy number decreased significantly compared 
to baseline in all 12 patients (p < 0.01, Fig. 3), and became 
undetectable (n =  7) or  <1  % (n =  5) after a median of 
13  days (range 6–40  days). At the time when no ctDNA 
could be measured any more, none of the patients had 
obtained a complete radiological remission (e.g. Fig.   4a, 
e). In 3 patients, BRAF V600mut ctDNA remained detect-
able from the initiation of targeted therapy until PD was 
diagnosed (e.g. Fig. 4b). Median PFS was not significantly 
longer for patients in whom BRAF V600mut ctDNA 
became undetectable  1  month after the initiation of tar-
geted therapy, as compared to patients in whom ctDNA 
remained detectable during the first month of therapy 
(p  =  0.56). Progression free survival was significantly 
shorter for patients in whom BRAF V600mut ctDNA 
remained detectable throughout the treatment with tar-
geted therapy compared to patients in whom BRAF 
V600mut ctDNA became undetectable (p < 0.001) (Fig. 5).  
Table 1 Patient baseline characteristics (n = 36)
Data are mean (SD) or n (%).
Baseline characteristics at the moment of collection of the first plasma sample
a Eight patients were treated with dabrafenib and trametinib after 
documentation of disease progression at least 12 weeks following the last day 





 Male 12 (33 %)
 Female 24 (67 %)
Stage
 IVa 4 (11 %)
 IVb 2 (6 %)
 IVc 30 (83 %)
Primary site
 Cutaneous 28 (78 %)
 Acral 4 (11 %)
 Mucosal 0 (0 %)
 Unknown 4 (11 %)
Treatment
 Dabrafenib + trametinib 34 (94 %)
 Dabrafenib 2 (6 %)
 Vemurafenib 0 (0 %)
 Re-challenge dabrafenib + trametiniba 8 (22 %)
First plasma sample
 Before initiation of targeted therapy 16 (44 %)
 After initiation of targeted therapy 20 (56 %)
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Correlation between BRAF V600 mutant ctDNA levels 
and disease progression
During the course of plasma BRAF V600mut ctDNA 
monitoring, clinical PD was diagnosed in 27 of 36 
patients after a median of 111  days [95  % CI 98–124] 
(Figs. 1b, 6). An increase of the BRAF V600mut ctDNA 
copy number and fraction was diagnosed in 19 of 27 
(70 %) patients with PD and in none of the patients with 
an ongoing response, resulting in a sensitivity of 70 % and 
a specificity of 100 % (Kappa 0.54 [0.26–0.82]).
In 30  % (n  =  8/27) of patients, no BRAF V600mut 
ctDNA was detected at the time of clinical PD. Of these 
eight patients, three showed PD in the brain (2 asymp-
tomatic, e.g. Fig. 4e) and five showed slow PD in a single 
subcutaneous, bone, muscle or lung lesion.
An increase in the BRAF V600mut ctDNA fraction was 
detected prior to the clinical diagnosis of PD in 12 out 
of 27 (44  %) patients and simultaneously with PD in 7 
out of 27 (26 %) patients. The first increase in the BRAF 
V600mut ctDNA fraction, after the BRAF V600mut 
Fig. 1 a Flow diagram showing subgroups of patients according to the detection of BRAF V600mut ctDNA after treatment initiation. b Flow dia-
gram showing subgroups of patients according to the evolution of BRAF V600mut ctDNA in relation to disease progression. Pts patients
(See figure on next page.) 
Fig. 2 Serial measurement of BRAF V600mut ctDNA in plasma of 2 patients (a, b = patient 1; c, d = patient 2) with advanced melanoma during 
targeted therapy. The y-axis represents the BRAF V600mut ctDNA copy number per millilitre. Results obtained with the Idylla™ system (Biocartis) 
and digital PCR (Bio-rad) are shown.  a Treatment with dabrafenib and trametinib (dabra 2 × 150 mg + trame 2 mg) was initiated after obtain-
ing the baseline plasma sample. Within 1 week the BRAF V600mut ctDNA copy number dropped significantly. After switching targeted therapy to 
pembrolizumab (Pem 2 mg/kg) due to side effects on the moment of best response (PR PET–CT), an increase of the BRAF v600mut ctDNA copy 
number was detected within 9 days. After reintroducing dabrafenib and trametinib, due to rapid clinical disease progression (Clinical PD), the BRAF 
V600mut ctDNA copy number dropped again. b The evolution of the BRAF V600mut ctDNA copy number in patient 1 during the first 2 days of 
treatment. c Treatment with dabrafenib and trametinib (dabra 2 × 150 mg + trame 2 mg) was initiated after obtaining the baseline plasma sample. 
Within 1 week the BRAF V600mut ctDNA copy number dropped significantly. d The evolution of the BRAF V600mut ctDNA copy number in patient 2 
during the first day of treatment
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ctDNA fraction became undetectable or was decreasing, 
was detected after a median of 74 days [95 % CI 19–130] 
from the collection of the first plasma sample. The 
median interval between the first increase in the BRAF 
V600mut ctDNA fraction and PD was 25 days [95 % CI 
1–48 days]. A first increase in the BRAF V600mut ctDNA 
fraction or copy number predicted PD within the fol-
lowing month in 63 % of patients (n = 12/19; p < 0.001) 
and within the following 2  months in 100  % of patients 
(n = 19/19; p < 0.001).
When BRAF V600mut ctDNA could not be detected in 
plasma (n =  173 samples), PD did not occur in the fol-
lowing month in 86 %, and not in the following 2 months 
in 76 % of cases. Out of the four patients with no detecta-
ble BRAF V600 ctDNA at baseline, three patients showed 
PD during follow-up, and in two of these patients BRAF 
V600mut ctDNA was detected simultaneously with or 
before prior to PD on imaging. (Fig. 4c, d).
Discussion
In this study, BRAF V600mut ctDNA was detected at 
baseline in 75  % of stage IV melanoma patients with 
a known BRAF V600 mutation. This is in line with two 
other studies using PCR based methods, where BRAF 
V600mut ctDNA was detected in plasma of 73–84 % of 
BRAF V600 mutant melanoma patients [6, 25]. These 
results are also in line with an overall detection rate of 
77 % in 4 clinical studies with 746 stage IV BRAF V600 
mutant melanoma patients using BEAMing (beads, 
emulsions, amplification, and magnetics analysis) after 
Fig. 3 a Individual evolutions in the BRAF V600mut ctDNA fraction from initiation of treatment with dabrafenib (150 mg BID) and trametinib (2 mg 
QD), at baseline (BL) to the first visit (FV). b Individual evolutions in the BRAF V600mut ctDNA copy number from initiation of treatment with dab-
rafenib (150 mg BID) and trametinib (2 mg QD) at baseline (BL) to the first visit (FV)
(See figure on next page.) 
Fig. 4 Serial measurement of BRAF V600mut ctDNA from plasma in 5 patients (a–e) with advanced melanoma during targeted therapy. Treat-
ment with dabrafenib (dabra, 150 mg BID) and trametinib (trame, 2 mg QD) was initiated after obtaining the baseline plasma sample. The left y-axis 
represents the BRAF V600mut ctDNA copy number per milliliter (solid line), the right y-axis represents the BRAF V600mut ctDNA fraction to the total 
amount of cfDNA (dashed line). SD, PR and PD respectively denote stable disease, partial response and progressive disease according to RECIST 
v1.1. a The BRAF V600mut ctDNA copy number and fraction dropped after treatment initiation. After 40 days, no BRAF V600mut ctDNA could be 
detected anymore, and CT body showed a PR. The BRAF V600mut ctDNA fraction reappeared after 96 days and increased on day 124, although 
an ongoing PR was reported on PET–CT. PET–CT showed PD, 50 days after the reappearance of BRAF V600mut ctDNA in plasma. b BRAF V600mut 
ctDNA remained detectable from treatment initiation until PD was detected after 89 days. c At baseline, no BRAF V600mut ctDNA was detected 
in plasma. BRAF V600mut ctDNA appeared after 28 days, 35 days prior to the detection of PD on CT body. d At baseline, no BRAF V600mut ctDNA 
was detected in plasma. After 168 days, PD was detected in a gallbladder metastasis, and BRAF V600mut ctDNA was detected concomitantly. The 
only other lesion, a lung metastasis, had remained strictly stable. After resection of the gallbladder metastasis, the BRAF V600mut ctDNA fraction 
could not be detected until PD occurred in the remaining lung metastasis. e Five days after treatment initiation, BRAF V600mut ctDNA could not be 
detected anymore. Brain MRI showed a new millimetric brain lesion on the first response evaluation, while PET–CT showed clear regression of all 
liver and lung metastases. Subsequent MRI’s showed ongoing slow PD in the brain, while liver and lung lesions showed ongoing PR. No BRAF  
V600mut ctDNA was detected during PD in this patient
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cfDNA extraction from plasma [26–30]. Moreover, one 
study showed a 100  % agreement between digital PCR, 
qPCR and BEAMing, suggesting that the suboptimal 
detection rate of BRAF V600 mutant DNA in plasma in 
advanced melanoma is the result of a variable amount of 
BRAF V600mut ctDNA in advanced melanoma patients, 
rather than an variability in the sensitivity of different 
test-platforms [25]. We observed that after initiating 
BRAF/MEK inhibitor treatment, BRAF V600mut ctDNA 
can drop below the detection limit, notwithstanding 
the absence of radiological complete remission. This 
phenomenon of rapid decrease in the concentration of 
BRAF V600mut ctDNA has been reported before and 
has been attributed to the destruction of tumor cells 
and a subsequent rapid clearance of ctDNA [6, 31–33]. 
Our combined observations of (1) decrease of the BRAF 
V600mut ctDNA concentration within days after treat-
ment initiation, (2) of early increase during disease pro-
gression and (3) of early increase after discontinuation of 
targeted therapy, are suggestive of a correlation between 
ctDNA levels and the proliferation of melanoma cells. 
Therefore BRAF V600mut ctDNA seems to reflect the 
BRAF V600mut-dependent proliferative tumor burden, 
and not tumor mass as evidenced by CT-imaging. From 
this perspective, ctDNA could be attributed to increased 
cell death during melanoma cell proliferation or might 
be actively secreted or passively released by living cells, 
rather than by apoptotic or necrotic cells [34]. This latter 
hypothesis is supported by several preclinical arguments. 
Spontaneous active DNA release or apoptosis have 
been put forward as the main source of ctDNA, because 

































BRAF V600mut ctDNA 
remained detectable after 
treatment initiation
p < 0.001
Fig. 5 Kaplan–Meier plot representing the progression-free survival probability for patients with advanced melanoma in whom BRAF V600mut 
ctDNA became undetectable after initiation of a BRAF inhibitor containing treatment regimen (solid line), and for patients in whom BRAF V600mut 
ctDNA remained detectable during follow-up (dashed line)
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active cleaving, when subjected to electrophoresis [32, 
35]. Several arguments support the hypothesis that DNA 
is primarily released by living cancer cells rather than by 
apoptotic cancer cells: (1) DNA concentration increases 
in normal lymphocyte cultures following stimulation 
with phytohemagglutinin, lipopolysaccharide or antigen; 
(2) in a leukemic cell-line malignant cells released newly 
synthesized DNA; (3) cancer cell DNA concentration in 
cell culture supernatant increases with cell proliferation 
when few apoptotic or necrotic cells are present; and (4) 
circulating exosomal BRAF V600E mutant DNA was iso-
lated from SK-MEL-28 melanoma-bearing mice [32, 33, 
36, 37].
In our study population, PFS was significantly better 
for the patients in whom BRAF V600mut ctDNA became 
undetectable after the initiation of targeted therapy. 
When the BRAF V600mut ctDNA fraction increased 
during treatment, clinical PD always followed within 
2 months. Moreover, in 44 % of cases an increase in the 
mutant fraction preceded PD. We recently reported 
that reappearance of BRAF V600mut ctDNA in plasma 
cfDNA can precede changes on PET–CT in patients 
under BRAF/MEK inhibitor treatment [34]. In this 
study an increase in the BRAF V600mut ctDNA frac-
tion preceded PD with a median interval of 25  days. 
However, plasma samples were collected on a monthly 
basis, whereas imaging was performed every 2  months. 
In a study on ctDNA monitoring in metastatic breast 
cancer, increasing levels of ctDNA appeared on average 
5  months before the establishment of PD by means of 
imaging [3].
An increase in the BRAF V600mut ctDNA fraction 
during BRAF/MEK targeted therapy could potentially 
serve as a trigger for early evaluation with imaging tech-
niques, and allow for a timely switch to immunotherapy 
or other appropriate therapeutic interventions (e.g. 
Fig. 6 Swimmer plot showing the interval between increase of the BRAF V600mut ctDNA fraction and progressive disease according to RECIST v1.1 
on imaging (PD), for all 36 patients patients from start of ctDNA monitoring. In 12 patients, an increase in the BRAF V600mut ctDNA fraction was 
detected prior to PD. In 7 patients, an increase of the BRAF V600mut ctDNA fraction was detected simultaneously with PD. In 8 patients, no increase 
in the BRAF V600mut ctDNA fraction was detected prior to or simultaneously with PD. None of the patients with an ongoing response showed an 
increase of the BRAF V600mut ctDNA fraction
Page 10 of 11Schreuer et al. J Transl Med  (2016) 14:95 
stereotactic radiotherapy to brain metastases). Early 
detection of progression is important in metastatic mel-
anoma, because of the aggressive course of the disease 
as exemplified by the observation that the central nerv-
ous system is a frequent site (30  %) of first progression 
under BRAF inhibitor therapy [17]. Moreover, potential 
second line therapeutic options such as ipilimumab and, 
to a lesser extent anti-PD-1 therapies, are associated with 
a latency of their anti-tumor effect. Therefore, the possi-
bility of offering immunotherapy may be compromised if 
PD is only detected on imaging or when clinical symp-
toms are present [19, 20].
Conclusions
Our results indicate that quantitative analysis of BRAF 
V600mut ctDNA in plasma holds promise as a monitor-
ing tool in BRAF V600 mutant melanoma during treat-
ment with BRAF/MEK targeted therapy. Prospective 
trials are needed to assess if an add-on strategy or switch 
to immunotherapy upon early detection of therapy resist-
ance through ctDNA evolution, adds value to the current 
treatment strategies. Finally we provide clinical argu-
ments suggesting that an important fraction of BRAF 
V600mut ctDNA correlates with the BRAF V600mut-
dependent proliferative tumor burden.
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